Schmidt Thomas, Belyaev Orlin, Uhl Waldemar, Bruns Christiane J
Klinik und Poliklinik für Allgemein‑, Viszeral‑, Tumor- und Transplantationschirurgie, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Klinik für Allgemein- und Viszeralchirurgie, St. Josef-Hospital, Universitätsklinikum, Ruhr-Universität Bochum, Bochum, Deutschland.
Chirurg. 2022 May;93(5):446-452. doi: 10.1007/s00104-022-01618-7. Epub 2022 Mar 31.
The incidence of pancreatic ductal adenocarcinoma is continuously increasing and will become the second leading cause of cancer-related death in Europe and the USA by 2030. With a 5-year overall survival rate of less than 10% the prognosis remains poor. So far surgical tumor resection remains the only curative treatment option, which is now partially supported by multimodal neoadjuvant and adjuvant therapy concepts. Due to the aggressive tumor biology patients with advanced pancreatic cancer in particular can profit from these multimodal therapy concepts. Additionally, in recent years surgical treatment was optimized, the criteria for tumor resectablity were defined and minimally invasive surgery was widely introduced. This review article summarizes the newest developments and the new German S3 guidelines concerning surgery of pancreatic cancer.
胰腺导管腺癌的发病率持续上升，到2030年将成为欧美地区癌症相关死亡的第二大主要原因。其5年总生存率低于10%，预后仍然很差。到目前为止，手术切除肿瘤仍然是唯一的治愈性治疗选择，现在多模式新辅助和辅助治疗理念为其提供了部分支持。由于肿瘤生物学行为侵袭性强，尤其是晚期胰腺癌患者可从这些多模式治疗理念中获益。此外，近年来手术治疗得到了优化，明确了肿瘤可切除性标准，并广泛引入了微创手术。这篇综述文章总结了胰腺癌手术的最新进展以及新的德国S3指南。
